Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management
The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
